Physician profile
Erin Pearson
NPI 1629658232
$4,159.66
in general payments reported to CMS, 2019-2025
38 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $313 · 2024: $2,224 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,337 · Consulting Fee: $640 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.67 |
| Consulting Fee | $640.00 |
| Education | $182.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.70 | 2024-2025 | |
| Genentech USA, INC. | $436.00 | 2023-2025 | Venclexta, Polivy |
| Novartis Pharmaceuticals Corporation | $322.65 | 2023-2025 | |
| Pfizer INC. | $242.60 | 2023-2025 | |
| Celgene Corporation | $216.96 | 2024-2025 | Reblozyl, Pomalyst, Breyanzi |
| Astrazeneca Pharmaceuticals LP | $208.42 | 2023-2025 | Calquence |
| Janssen Biotech, INC. | $156.66 | 2024 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $154.13 | 2024-2025 | Vanflyta |
| Genzyme Corporation | $134.48 | 2024-2025 | |
| Genmab U.S., INC. | $128.59 | 2023-2025 | Epkinly |
| Astellas Pharma US INC | $125.78 | 2025 | Vyloy |
| Syndax Pharmaceuticals, INC. | $121.91 | 2025 | Revuforj |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Talvey |
| Adc Therapeutics America, INC. | $107.70 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $97.73 | 2023-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $97.33 | 2024 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $81.62 | 2023-2025 | Iclusig, Ninlaro |
| Sobi, INC | $80.29 | 2024-2025 | |
| Incyte Corporation | $79.22 | 2023-2024 | Monjuvi |
| Lilly USA, LLC | $77.51 | 2023-2025 | Jaypirca, Retevmo, Verzenio |
| Secura Bio, INC. | $66.28 | 2025 | Copiktra |
| Legend Biotech USA INC. | $62.50 | 2025 | Carvykti |
| Taiho Oncology, INC. | $62.11 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $60.78 | 2024-2025 | Reblozyl, Keytruda |
| Karyopharm Therapeutics INC. | $55.24 | 2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $49.49 | 2023 | Imbruvica |
| Agios Pharmaceuticals, INC. | $49.22 | 2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $46.28 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Glaxosmithkline, LLC. | $40.38 | 2025 | Ojjaara |
| Blueprint Medicines Corporation | $40.11 | 2025 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $34.54 | 2023 | Provenge |
| Jazz Pharmaceuticals INC. | $31.55 | 2024 | |
| Stemline Therapeutics INC. | $24.20 | 2025 | Elzonris |
| Pharmaessentia USA Corporation | $22.78 | 2024 | Besremi |
| Geron Corporation | $22.39 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $20.93 | 2025 | Brukinsa |
| Beigene USA, INC. | $20.39 | 2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $16.21 | 2024 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.